Never been a more critical time for Nader to be silent.
The catalysts that are in play are clear to the market. No need to reiterate the facts on Proactive Investor. All one has to do is replay the Tedx Talk if they need clarity on where Leronlimab is positioned.
The CD-10 mild to moderate trial results combined w the 50 patient interim on the severe CD-12 trial is the tipping point and it’s T minus 21 days and counting. The company knows it, Big Pharma knows it, while the market is digesting the potential valuation with each passing day.
At this very moment the inflection point is just prior to the July 22 SH’s meeting to authorize an additional 100M shares. Nader chose the date knowing the likelihood of CYDY’s valuation being well above $10 is a safe bet.
This gives Nader infinite options to raise $. He will not be pushed into a corner w access to 100M shares.
My how far we have come from raising at .30 w matching warrants as a sweetener. Welcome to CYDY 2.0 and the reality of Leronlimab’s present and future valuation.
The infamous AF is biting his nails down to the quick trying to contrive an inspiring a spin that can turn the tide. Problem is he has to manipulate the reality without touching the science.
When AF does pounce, and he will prior to the trial results being disclosed, their will be a powerful rebuttal ready for print that will bury this POS.
Movie Theaters are closed. Who cares — CYDY is the best show in town hands down.
